



Neuren (NEU) – ASX Announcement

17 February 2021

Neuren investor briefing webinar

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) CEO Jon Pilcher & Chairman Patrick Davies will conduct an investor briefing webinar on Wednesday 24 February 2021 commencing at 11.00 AEDT.

To participate in this free event, which is hosted by Monsoon Communications and sponsored by FB Rice, investors should register via the following link:

https://us02web.zoom.us/webinar/register/WN_mfHnompSSj-dNbVBLMA9g

About Neuren

Neuren is developing two new drug therapies to treat multiple serious neurological disorders that emerge in early childhood, none of which have any approved medicines.

The lead drug compound, trofinetide, is currently in a Phase 3 clinical trial for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. Both programs have been granted Fast Track designation by the US Food and Drug Administration (FDA). Neuren has granted an exclusive licence to ACADIA Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America.

Neuren plans to initiate Phase 2 trials of its second drug candidate, NNZ-2591, for each of Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome in 2021.

Because of the urgent unmet need, all five programs have been granted “orphan drug” designation in both the United States and the European Union, a designation that provides incentives to encourage therapies for rare and serious diseases.

Contacts:

Jon Pilcher, CEO: jpilcher@neurenpharma.com; +61 438 422 271

Rudi Michelson, Monsoon Communications: rudim@monsoon.com.au; +61 411 402 737

ASX Listing Rules information

This announcement was authorised to be given to the ASX by the CEO of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124